A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)

Investigator: Shilpan Shah, MD

Study Coordinator: Danielle Grbavac

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT05254743

Phone: 346.238.4456

Protocol Number: PRO00036354


The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants may or may not have already had treatment for their cancer. Participation could last up to six years.
More to Explore